What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
Parkinson's disease, Genetics, Parkin, Substantia nigra and Internal medicine are his primary areas of study.
His Parkinson's disease research is multidisciplinary, incorporating perspectives in Dopaminergic, Neurodegeneration, Neuroscience, Mitochondrion and Degenerative disease.
His Genetics study frequently draws parallels with other fields, such as Parkinsonism.
The concepts of his Parkin study are interwoven with issues in Molecular biology, Ubiquitin, Ubiquitin ligase and Cell biology.
His Substantia nigra study is concerned with the larger field of Pathology.
His work on Endocrinology expands to the thematically related Internal medicine.
His most cited work include:
- Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (4066 citations)
- Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium (3883 citations)
- Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase (1717 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Parkinson's disease, Internal medicine, Genetics, Pathology and Parkin.
His biological study spans a wide range of topics, including Neuroscience and Degenerative disease.
His Internal medicine research integrates issues from Gastroenterology, Endocrinology and Cardiology.
His study looks at the intersection of Genetics and topics like Parkinsonism with Dementia.
He interconnects Lewy body, Ubiquitin, Ubiquitin ligase, Molecular biology and Cell biology in the investigation of issues within Parkin.
His research in Substantia nigra tackles topics such as MPTP which are related to areas like Pharmacology.
He most often published in these fields:
- Parkinson's disease (27.92%)
- Internal medicine (17.63%)
- Genetics (16.75%)
What were the highlights of his more recent work (between 2003-2020)?
- Parkinson's disease (27.92%)
- Genetics (16.75%)
- Parkin (13.79%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Parkinson's disease, Genetics, Parkin, Pathology and Internal medicine.
His studies deal with areas such as Neuroscience, Pathogenesis and Degenerative disease as well as Parkinson's disease.
His Genetics study combines topics in areas such as Disease and Parkinsonism.
The Parkinsonism study which covers Dementia that intersects with Pediatrics.
His Parkin study incorporates themes from Ubiquitin, Ubiquitin ligase, Neurodegeneration and Age of onset.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Endocrinology and Cardiology.
Between 2003 and 2020, his most popular works were:
- Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium (3883 citations)
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (726 citations)
- Mitochondrial Genome Variation in Eastern Asia and the Peopling of Japan (432 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
His primary areas of investigation include Parkinson's disease, Genetics, Parkin, Pathology and Substantia nigra.
His Parkinson's disease research incorporates themes from Cerebral cortex, Neuroscience, Placebo and Adverse effect.
His work in Genetics addresses subjects such as Disease, which are connected to disciplines such as Single-nucleotide polymorphism and Allele.
Parkin is a subfield of Internal medicine that Yoshikuni Mizuno studies.
His research investigates the connection with Pathology and areas like Proband which intersect with concerns in Exon.
The various areas that he examines in his Substantia nigra study include Oxidative stress, Molecular biology, Genetic enhancement and Microglia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
